In-Depth Review on Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017
Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.
Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.
Complete report available @ Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 10 and 9 molecules, respectively.
Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease)
- The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Advinus Therapeutics Ltd BioLingus AG Daiichi Sankyo Company Ltd iCo Therapeutics Inc. Laboratorios LETI SL ManRos Therapeutics Matinas BioPharma Holdings Inc Nanomerics Ltd Novartis AG Oblita Therapeutics BVBA
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 00:07
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home